autologous CD19/CD22 dual-target CAR-T module / Beijing Biotech - LARVOL DELTA

ADAPT-HEM: Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=96 | Recruiting | Sponsor: Beijing Biotech

Biomarker • IO biomarker • New P1/2 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Plasma Cell Leukemia • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • T-cell Acute Lymphoblastic Lymphoma